Compare Ginkgo Bioworks Holdings Inc (DNA) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $505.73M), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.91. The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | PDBC | |
|---|---|---|
Market Cap | $505.73M | — |
Sector | Health | — |
52-Week High | $16.14 | $18.91 |
52-Week Low | $5.48 | $12.90 |
Enterprise Value | $607.68M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
PDBC, an ETF tracking diversified commodities, trades at $17.25, up 0.12% with a bearish technical signal. Recent news highlights institutional inflows, such as Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (Defense World, 2026-07-19), and a Seeking Alpha downgrade to hold due to weakening commodity momentum (2026-06-11). The ETF has outperformed the S&P 500 by nearly 10 percentage points since March 2024 but faces headwinds from oil price declines and geopolitical tensions.
Outlook is mixed: commodities offer inflation hedging potential, with PDBC surging 50% amid supply disruptions (24/7 Wall Street, 2026-05-11), but risks include a potential 'super-squeeze' from Middle East conflicts (HSBC via 24/7 Wall Street, 2026-07-24) and tax-related complexities. Investors should weigh diversification benefits against volatile commodity cycles and roll costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
